Novartis drug Rhapsido is now approved as a second-line treatment for chronic spontaneous urticaria, a rare inflammatory skin disease. Additional clinical trials are ongoing to support potential expansion of the twice-daily pill to other immunological disorders. The post Novartis Nabs FDA Approval for First-of-Its-Kind Drug for Chronic Hives appeared first on MedCity News.
By MATTHEW HOLT So I am back dealing with Labcorp & Blue Shield of California over the mysterious $34 copay. If you want to catch up go here Over the weekend Labcorp sent me a final due notice on my bill…. the one that they couldn’t tell me about without asking for all the information…
CHARLESTON, W.Va. — More than three years have passed since federal health officials arrived in central Appalachia to assess an alarming outbreak of HIV spread mostly between people who inject opioids or methamphetamine. Infectious disease experts from the Centers for Disease Control and Prevention made a list of recommendations following their visit, including one to…
The acquisition comes after a rough two years for Florida-based Cross Country
In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid-19, the FDA said its policy will compel generation of more evidence for these groups. Our roundup of regulatory news includes notable firsts for Alzheimer’s diagnosis and migraine treatment. The post New FDA…
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed on “CBS Mornings Plus” on June 10 how Health and Human Services Secretary Robert F. Kennedy Jr.’s removal of members of the CDC vaccine advisory committee could affect public health. Click here to watch Gounder on “CBS Mornings Plus” Freelance journalist and KFF Health News…
[Sponsored] Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond. The post The Top Surgical Instruments Needed for Extractions appeared first on MedCity News.
Spending on digital health has increased rapidly over past two years
Repare Therapeutics is cutting discovery and preclinical work to focus on its clinical-stage cancer drugs. The most advanced program is camonsertib, whose rights Repare recently regained from Roche after the pharma giant terminated an alliance started in 2022. The post Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline appeared first on MedCity News.
Investigation targeted HCA’s training repayment agreement provisions in nurses’ employment contracts